Myocilin and optineurin are two genes linked to glaucoma, a major blinding disease characterized by progressive loss of retinal ganglion cells and their axons. This review describes the characteristics of myocilin and optineurin protein products and summarizes the consequences of ectopically expressed wild-type and mutant myocilin and optineurin in trabecular meshwork and/or neuronal cells. Myocilin and optineurin exhibit differential characteristics and have divergent functional consequences. They contribute to the development of glaucoma probably via distinct mechanisms.
Introduction
Glaucoma is one of the leading causes of irreversible blindness worldwide. This disease is characterized by progressive loss of retinal ganglion cells (RGCs) and accompanying axons. Primary open-angle glaucoma (POAG), the most common form of glaucoma, is frequently associated with increased intraocular pressure (IOP). The IOP is controlled by a balance between the production and outflow of the aqueous humor contained in the anterior chamber. The trabecular meshwork (TM), a specialized tissue, is the major site for regulation of the aqueous humor outflow. 1, 2 Studies over the past decades have revealed that POAG is genetically heterogeneous, caused by several susceptibility genes and environmental factors. 3, 4 To date, a total of 15 chromosomal loci have been mapped and designated as GLC1A to GLC1O. 3À7 Four candidate genes have been identified that include myocilin as the GLC1A, 6 optineurin as the GLC1E, 7 WDR36 as the GLC1G, 3, 4 and neurotrophin-4 as the GLC1O 3,4 gene.
Myocilin is the first identified gene for both juvenile-and adultonset POAG. 6 More than 70 myocilin mutations have been found in several families. 3, 5 Glaucoma patients with myocilin mutation tend to have high IOP. 5 Among the myocilin mutations, the Gln368Stop (Q368X) mutation is the most frequent 8 and the Pro370Leu (P370L) mutation is responsible for one of the most severe glaucoma phenotypes.
Optineurin is a gene that links principally to normal tension glaucoma (NTG), a subtype of POAG. 7 Optineurin mutations are noted to vary with ethnic background. 9 The Glu50Lys (E50K) mutation, found in Caucasian and Hispanic populations, 9 seems to be associated with a more progressive and severe disease in NTG patients. 10 
Gene structure and expression
The myocilin gene contains three exons and two introns that span 17 kb pairs. 11 The protein product encoded by the human gene contains 504 amino acids. There is a hydrophobic signal peptide sequence (amino acids or aa 1e32) and non-muscle myosinlike domain near the amino (N)-terminus and an olfactomedin-like domain (aa 326e501) at the carboxyl (C)-terminus. The N-terminus has two initiation sites. Within the myosin-like domain, there are leucine zipper motifs within two coiled-coil regions (aa 74e110 and aa 118e186). 11, 12 The leucine zipper and the olfactomedin domains are well conserved across species. At the secondary level, the N-terminal region is primarily a-helical and the C-terminal consists mostly of b-strands. 13 In glaucoma patients, most of the myocilin mutations are mapped to the third exon of the gene within the C-terminal olfactomedin domain. The expression of myocilin is mainly in the eye, but it has also been observed in several other tissues in the body including the skeletal muscle and brain. In the eye, myocilin is seen in many tissues such as the sclera, ciliary body and the optic nerve head, 14 although its expression is the highest in the TM.
The human optineurin gene has a total of 16 exons; the first 3 are non-coding and the remaining 13 exons code for a 577-amino acid protein that contains multiple coiled-coil domains and a C-terminal zinc finger. 15, 16 The optineurin protein from different species has high amino acid homology. 16 The amino acid 50 glutamic acid residue is conserved in mouse, rat, chicken and cow. Optineurin is also ubiquitously expressed in non-ocular tissues such as the heart and brain, and in ocular tissues including the retina, trabecular meshwork and non-pigmented ciliary epithelium. In the retina, RGCs are immunolabeled with high intensity.
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Protein characteristics
Myocilin was initially identified as a protein secreted into the media of TM cultures after induction with glucocorticoids such as dexamethasone (DEX). 12 One unique feature is that myocilin expression is highly upregulated by DEX in TM cells but not in other cell types such as corneal fibroblasts. 11, 17 Containing a signal peptide sequence at the N-terminus, myocilin is, at least in part, secreted via the traditional secretory pathway. Myocilin has additionally been shown to associate with exosome-like vesicles and may also use this alternative mechanism to be released from the cell.
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Myocilin has been shown to be a glycoprotein, N-glycosylated at amino acid residues 57e59 (Asn-Glu-Ser). 11 On Western blots, it is seen as 53e57 kDa doublet bands although some antibodies also yield a 66-kDa protein band. When subjected to membrane protein extraction, myocilin in TM cell lysates distributed largely in the hydrophobic fraction in association with membranes ( Fig. 1) . The myocilin protein has also been reported to be cleaved into a 20-kDa N-terminal fragment and a 35-kDa C-terminal fragment both in vitro and in vivo. The proteolytic processing of myocilin is suggested to have a role in regulating its molecular interactions. 18 Myocilin interacts with itself at sites of the leucine zipper/ coiled-coil domain to form dimers and possibly multimers. 11, 19, 20 It also interacts with several proteins including flotillin-1 (a structural protein of lipid rafts), optimedin, extracellular proteins such as fibronectin and fibrillin-1, as well as matricellular proteins hevin and SPARC. 11, 18 Optineurin, by contrast, is not secreted. 21 It is neither N-nor O-glycosylated but is serine-and tyrosine-phosphorylated. 22 Optineurin is shown to be, exclusively, a hydrophilic, cytosolic protein. 22 It possesses a ubiquitin-binding domain, is ubiquitinated and is processed through the ubiquitineproteasome pathway. 22, 23 By native blue gel electrophoresis, optineurin is found to be capable of forming 420 kDa homo-oligomers, which, based on the 67-kDa monomer size, is estimated to be hexamers. 22 Furthermore, optineurin interacts and associates with Rab8, myosin VI and transferrin receptor, 22, 24 either singly or in combination, to form supermolecular complexes with sizes larger than 400 kDa. 22 Optineurin has also been shown to interact with transcription factor IIIA, 25 huntingtin, 26 metabotropic glutamate receptor 27 and TANK-binding kinase 1 (TBK1). 28 It shares 53% amino acid homology with NEMO (NF-kB essential modulator) and is identified as a NEMO-related protein. 29 Optineurin expression is upregulated by tumor necrosis factor-a (TNFa) 15 and interferon and its phosphorylation is induced upon phorbol 12-myristate 13-acetate stimulation. 29 
Localization
Myocilin protein is localized to both intracellular and extracellular sites in TM cells. Immunofluorescence has shown that the intracellular form of myocilin is diffusely distributed in the cytoplasm including perinuclear regions.
11,17 Subcellular fractionation and/or immunoelectron microscopy indicated that intracellular myocilin in TM cells is associated not only with endoplasmic reticulum, Golgi apparatus, vesicles but also with mitochondria.
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Immunogold labeling documented the extracellular localization of myocilin. 11, 31, 32 It is intriguing that, in TM tissues, myocilin is mainly associated with microfibrillar architecture in sheath-derived plaques where pathologic changes have been reported to occur in the eyes of POAG patients. 32 Optineurin also has a diffuse, cytoplasmic distribution but a proportion of the protein is associated with the Golgi apparatus. 21 As optineurin is a cytosolic protein not associated with membranes, the optineurineGolgi association is probably indirect via interactions of other Golgi-associated proteins such as Rab8. 22 5. Consequences of overexpression and mutation and/or possible functional roles
Deadhesive activity, Rho inactivation, mitochondrial association and inhibition on neurite outgrowth: Myocilin phenotype
The extracellular myocilin was demonstrated to be a very poor substrate for TM cells. 33 It blocks the TM attachment to fibronectin, retards migration, causes a dramatic reduction in actin stress fibers and focal adhesions, 33, 34 and triggers TM cells to assume a stellate morphology with microspikes. 34 Myocilin has been shown to interact with fibronectin via the heparin (Hep) II domain. 35, 36 This domain, along with the Arg-Gly-Asp site, is where fibronectin is linked to the actin cytoskeleton, transducing signals from the exterior to the interior of the cells. The fibronectineTM cell interaction is possibly mediated via binding of myocilin to the Hep II domain. 36 Purified recombinant myocilin protein has also been more recently noted to be a modulator of Wnt signaling. 37 Overexpressing wild-type or full-length myocilin intracellularly 38 by transfection or by protein transduction 39 in TM cells results in an alteration in actin architecture, similar to that seen with the extracellular form of myocilin. Key findings include a loss of actin stress fibers and vinculin-positive focal adhesions, and a reduction in cell adhesion to fibronectin, vitronectin and collagen types I and IV. 40 The fibronectin deposition is diminished and the trypsinization time needed to round up or suspend TM cells from plates is significantly shorter for myocilin transfectants than that for mock controls, signifying compromised cellematrix adhesiveness. 40 Myocilin therefore appears to possess a deadhesive activity, capable of changing TM cells in culture from a state of strong adherence, containing robust focal adhesions and actin-containing stress fibers, to a state of compromised adhesiveness. The deadhesion process, on a long-term chronic basis, may render TM cells vulnerable. Myocilin-overexpressing cells have been shown to display an increased susceptibility to apoptotic challenge. 38 It is speculated that cell vulnerability, in conjunction with additional Fig. 1 . Western blot analysis for myocilin in hydrophilic and hydrophobic fractions of human TM cell lysates. Total proteins in TM lysates were subjected to membrane protein extraction followed by Western blotting. The hydrophobic fraction contained membrane proteins and the hydrophilic fraction contained predominantly nonmembrane cytosolic proteins. Myocilin (MYOC) in total cell lysates was detected largely in the hydrophobic fraction, although a small portion was also seen in the cytosolic, hydrophilic fraction. GM130, a Golgi marker used as a membrane protein positive control, was detected exclusively in the hydrophobic fraction.
stress or insults, may be a key factor in the development of glaucomatous conditions. When treated with lysophosphatic acid, a Rho stimulator, the fibronectin deposition in myocilin transfectants was enhanced, suggesting a role of small GTPase Rho family in the myocilin phenotype. 40 Subsequent pull-down assays indeed verify that the level of GTP-bound or active RhoA in myocilin transfectants is lower than that in controls. Further assays, in accordance with the notion that the regulation of Rho function represents a major target for protein kinase A (PKA) in cytoskeletal modulation, disclose that along with RhoA inactivation, the adenosine 3 0 ,5 0 -cyclic monophosphate level and the PKA activity are enhanced upon myocilin transfection. Inhibition of PKA by inhibitor H-89 in myocilintransfected cells prevents, at least partially, the stress fiber dissolution. Time lapse video microscopy corroborates that both the H-89 treatment and co-transfection with constitutively active RhoA delay the rounding up or prolong the trypsinization time of myocilin-green fluorescence protein (GFP)-expressing cells. 40 The association of myocilin with mitochondria was examined by mitochondrial import assays. 41 Cell free-translated myocilin was incubated with isolated mitochondria and the assays revealed that myocilin is robustly imported into the mitochondria isolated from TM cells, but only minimally into those from corneal fibroblasts and mouse liver. The myocilin imported into TM mitochondria is mostly targeted to the membranes. When upregulated or overexpressed, myocilin induces a drop of the mitochondrial membrane potential, indicative of mitochondrial depolarization or dysfunction. 41 The effect of myocilin on neurite outgrowth was investigated. 42 Neuronal PC12 and RGC5 cells were transfected to express myocilin-GFP and allowed to differentiate. Whereas the mocktransfected control cells produced long neurites, the length of neurites in wild-type myocilin-transfected cells was reduced to nearly half of that of controls. The number of neurites was likewise decreased. Myocilin mutant P370L and Q368X constructs also elicited inhibitory effects on neurite outgrowth, comparable to that seen with the wild-type myocilin. 42 Optineurin transfection, by contrast, has no effect on the actin structure, focal adhesion formation or trypsin sensitivity of the cells. 40 The PKA activity was also unaltered (Fig. 2) . Fig. 2 . PKA activity in optineurin-expressing cells. Human TM cells were transfected with pEGFP-N1 (GFP) or pOptineurin-GFP (OPTN-GFP) for 24 hours. Equal amounts of protein lysates were subjected to PKA assays. Positive (þ) and negative (e) controls were included. The non-phosphorylated (upper band, arrow) and the phosphorylated (lower band, arrowhead) substrates were resolved on agarose gels. The PKA activity in optineurin transfectants, indicated by the level of the phosphorylated substrate and determined by densitometric analyses, was similar to that in the GFP control. Unlike myocilin, optineurin is not imported into the mitochondria. 41 Neither overexpression nor mutation of optineurin results in any compromise of the mitochondrial membrane potential (data not shown). There was also no inhibitory effect on the neurite outgrowth. 42 5.2. Golgi fragmentation, impaired transferrin uptake, NF-kB pathway and inflammation regulation, and cell death: Optineurin phenotype
When transfected to express optineurin-GFP fusion protein, diffuse green fluorescence is seen in the cytoplasm of human retinal pigment epithelial (RPE), 21 RGC5, 22 PC12 42 and mouse neuroblastoma Neuro2a (Fig. 3) cells. Notably, bright granular or punctuate structures are also observed in perinuclear regions of all cell types. These structures, termed foci, are dynamic. Visualized by live cell imaging, they move around in both short and long ranges. 22 Subsequent experimentation using nocadazole proved that the formation of optineurin foci is microtubule-dependent. 21, 22 Such foci are likewise formed in cells after transfection to overexpress mutant E50K optineurin-GFP. The number and the size of the E50K-GFP foci are even greater than those of the wild type. 21 Golgi fragmentation was noted upon optineurin overexpression when the cells were immunostained with Golgi marker GM130 or Golgin97. The degree of fragmentation is also more severe in E50K transfectants than the wild type. 21, 22 Optineurin, as discussed above, is known to interact with Rab8, myosin VI, huntingtin and transferrin receptor; all are players in membrane trafficking. To determine the role of optineurin in protein trafficking, transferrin uptake, an indicator of receptor-mediated endocytosis process, was examined in RPE and RGC5 cells after transfection to overexpress wild-type and E50K optineurin. Results obtained indicated that the transferrin uptake was significantly decreased in optineurin-expressing cells. 43 The reduction was observed from the initial 2-and 5-minute time points. Cotransfection with transferrin receptor, but not Rab8 or myosin VI, construct rescued the optineurin inhibitory effect. The ectopic expression of optineurin caused transferrin receptor to colocalize with the foci. Surface biotinylation experiments further showed that the surface level of transferrin receptor was lowered, presumably leading to an impeded transferrin uptake. 43 The optineurin phenotype is probably mediated by the interaction between optineurin and transferrin receptor molecules. The E50K mutation, compared with the wild type, yielded a more pronounced impairment in the transferrin uptake. 43 Optineurin, sharing an amino acid homology with NEMO, is demonstrated to be a negative regulator of NF-kB. 44, 45 It is well known that transcription factor NF-kB is retained in an inactive form in the cytoplasm. Upon activation by TNFa, signaling intermediates such as RIP (receptor interacting protein) are recruited to the TNF receptor, resulting in activation of the IkB kinase (IKK) complex. The inhibitory proteins of the IkB family are then degraded and NF-kB is translocated to the nucleus to trigger gene regulation. NEMO is the catalytic unit known as IKKg of the IKK complex. Optineurin competes with NEMO for binding to ubiquitinated RIP to inhibit TNFa-induced NF-kB activation. There appears to be a negative feedback loop; optineurin gene expression is elevated by treatment of TNFa via the NF-kB pathway, and the optineurin induced in turn inhibits NF-kB activation, suggesting a physiological role for optineurin in dampening TNFa signaling. 44, 45 Via interaction with TBK1, optineurin has been shown to inhibit virus-triggered interferon-b induction. 46 Similar to NF-kB signaling, the ubiquitin binding domain of optineurin appears to be essential for regulation of the antiviral response. 46 The role of optineurin may therefore be expanded from a modulator of TNFa signaling to a broad-spectrum negative regulator of inflammation. Cell death ensued following optineurin overexpression. 42 Cell loss is, at least in part, due to increased apoptosis. 42 As is seen with other optineurin phenotypes, cell loss is also more pronounced in E50K-expressing cultures. As the E50K mutation generates much striking effects compared with the wild-type optineurin, this mutation is apparently a gainof-toxicity mutation. Defective trafficking, deregulated NF-kB signaling, along with fragmentation of the Golgi complex and induction of apoptosis, are speculated to be the underlying bases why E50K mutation renders the patients predisposed to glaucoma pathology.
Overexpression of wild-type myocilin results in diffuse distribution but little foci are observed in TM or RGC5 cells. No fragmentation of the Golgi is detected and the apparatus remains intact regardless of whether the cells were transfected with wild-type or mutant (P370L and Q368X) myocilin (Fig. 4) .
Unlike optineurin, wild-type myocilin does not affect transferrin uptake or its kinetics. 43 In addition, in contrast to optineurin, overexpression of wild-type myocilin does not invoke apoptosis in TM cells. 41 However, treatment of anti-Fas does induce a significantly higher level of apoptosis in myocilin-expressing cells compared with mock or non-transfected controls. 29 Myocilin overexpression appears to sensitize cells to apoptotic challenges. Of note is that P370L and Q368X myocilin mutants do trigger cell death. 42 These mutants are not secreted. 47 They are retained in the cells and have been shown to form aggregates to cause endoplasmic reticulum stress. 48 It is unknown whether myocilin plays a role in either NF-kB signaling/regulation or antiviral response.
Conclusions
Myocilin mutations are typically associated with high IOP cases and optineurin mutations are associated with NTG. As reviewed above, these two glaucoma genes are different, exhibiting dissimilar characteristics and eliciting differential effects on signal transduction, neurite outgrowth and protein trafficking process. The dissimilarity implicates that myocilin and optineurin have different functional roles and that they contribute to the development of neurodegenerative glaucoma via distinct mechanisms. Continued efforts directed at unraveling of such mechanisms are likely to be fruitful, providing further insights into the molecular bases involved in the pathogenesis of glaucoma.
